CEPI provides $30m to advance novel coronavirus vaccine
European Pharmaceutical Review
JULY 11, 2022
We are delighted to be working with CEPI to further this nanoparticle technology with the goal of producing efficacious, low-cost, infrastructure-independent vaccine that will be accessible to low- and middle-income countries.” . CEPI said it is committed to the principle of equitable access to the vaccines it funds.
94 
Let's personalize your content